News | September 02, 2022
NATCO Pharma to sell stake in Nativita and assets of Pharma division
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
New mass spectrometry instrument and consumables launch during IMSC 2022
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
The ninth acquisition since 2018
Subscribe To Our Newsletter & Stay Updated
